Radiation therapy may be safely omitted for patients with primary mediastinal B-cell lymphoma (PMBCL) who achieved a complete metabolic response after immunochemotherapy.
In the PHERGAIN trial, nearly all patients who were diverted from chemotherapy prior to surgery for HER2-positive early breast cancer survived without cancer recurrence for 3 years.
Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL.